NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









AusperBio

AusperBio

Private
San Francisco, CaliforniaHealthcare & Life Scienceshttps://ausperbio.com/

Last Round

Series B

Extension

Sep 21, 2025

Total Funding Raised

$236.7M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

AusperBio is a biopharmaceutical company that develops targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B and other liver diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

antisense oligonucleotideASOchronic hepatitis BCHBbiopharmaceuticaldrug developmentclinical trialsinfectious disease therapybiotechdrug discoveryviral replicationfunctional cureclinical-stage biotechtherapeutic pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

AusperBio Comps

Public and private peers based on sector, stage, and business model.

AusperBio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

AusperBio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series B ExtensionSep 21, 2025
Series B ExtensionMay 28, 2025
Series BDec 26, 2024
Series AJul 14, 2024
SeedNov 7, 2023

AusperBio Investors

Notable investors and investment history

AusperBio investors
InvestorRounds
CDH InvestmentsSeries B Extension, Series B
Genesis CapitalSeries B Extension
YuanBio Venture CapitalSeries B Extension, Series B, Series A
Genesis CapitalSeries B Extension, Series A
Sherpa CapitalSeries B Extension, Series B
Sherpa CapitalSeries B Extension, Series B
Hankang CapitalSeries B Extension, Series A, Series B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 1, 2026

    Monthly visitors grew 71% MoM, from 780 to 1.3K.

  • Nov 8, 2025

    Presented data at the AASLD 2025 conference.

AusperBio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

AusperBio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about AusperBio's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Francisco, California
Employee Range9
Year Founded2019
Last FundingSep 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.